Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)

Tipranks - Tipranks - Wed Apr 1, 6:24AM CDT

Analysts fell to the sidelines weighing in on Gilead Sciences (GILD), United Therapeutics (UTHR) and Jasper Therapeutics (JSPR) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

End of Quarter Sale - 50% Off TipRanks

Gilead Sciences (GILD)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences today and set a price target of $118.00. The company’s shares closed last Monday at $136.34.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 7.3% and a 48.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gilead Sciences with a $158.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

United Therapeutics (UTHR)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on United Therapeutics yesterday and set a price target of $471.00. The company’s shares closed last Monday at $588.36.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.8% and a 56.2% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Arvinas Holding Company, and Vertex Pharmaceuticals. ;'>

United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $616.50, a 1.9% upside from current levels. In a report issued on March 23, Wells Fargo also maintained a Hold rating on the stock with a $486.00 price target.

Jasper Therapeutics (JSPR)

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Hold rating on Jasper Therapeutics, with a price target of $4.00. The company’s shares closed last Monday at $0.90.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 13.2% and a 48.0% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. ;'>

Jasper Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.63, an 875.2% upside from current levels. In a report released today, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $0.89 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).